Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 13/20 | 0.56 |
| ▸ | HTR3A | P46098 | 3/20 | 0.54 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14436307 | 1.00 | CACNA1G (0.56) | CACNA1GHTR3AUTS2RHSD17B10KDM4E | |
| SCHEMBL12437833 | 0.92 | CACNA1G (0.60) | CACNA1GHTR3AUTS2R | |
| SCHEMBL12437829 | 0.90 | CACNA1G (0.54) | CACNA1GHTR3AUTS2RKDM4EALDH1A1 | |
| SCHEMBL12437831 | 0.89 | CACNA1G (0.52) | CACNA1GHTR3AUTS2RKDM4EALDH1A1 | |
| SCHEMBL12437828 | 0.88 | CACNA1G (0.55) | CACNA1GHTR3AUTS2RKDM4EALDH1A1 | |
| SCHEMBL12437830 | 0.85 | CACNA1G (0.53) | CACNA1GHTR3AUTS2RKDM4EALDH1A1 | |
| SCHEMBL12437710 | 0.85 | CACNA1G (0.49) | CACNA1GHTR3AUTS2RKDM4EALDH1A1 | |
| SCHEMBL12437826 | 0.85 | CACNA1G (0.55) | CACNA1GHTR3AKDM4EALDH1A1GLA | |
| SCHEMBL14436306 | 0.85 | CACNA1G (0.55) | CACNA1GHTR3AKDM4EALDH1A1GLA | |
| SCHEMBL12437963 | 0.84 | CACNA1G (0.52) | CACNA1GHTR3AHSD17B10KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | CACNA1G 4871/4885HTR3A 2752/4885UTS2R 854/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | CACNA1G 4871/4885HTR3A 2752/4885UTS2R 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.